Sign In
Buy HNSBF
$2.90
+0 (+0%)
At Close: Jul 31, 2026
Hansa Biopharma Ab Earnings Calls
Jun 30, 2026
-$0.263 (-659.64%)
| Release date | Jul 22, 2026 |
| EPS estimate | -$0.0346 |
| EPS actual | -$0.263 |
| EPS Surprise | -659.64% |
| Revenue estimate | 5.17M |
| Revenue actual | 4.94M |
| Revenue Surprise | -4.46% |
Mar 31, 2026
-$0.203 (-33.08%)
| Release date | Apr 23, 2026 |
| EPS estimate | -$0.153 |
| EPS actual | -$0.203 |
| EPS Surprise | -33.08% |
| Revenue estimate | 5.082M |
| Revenue actual | 3.64M |
| Revenue Surprise | -28.38% |
Dec 31, 2025
-$0.175 (-2.79%)
| Release date | Feb 11, 2026 |
| EPS estimate | -$0.171 |
| EPS actual | -$0.175 |
| EPS Surprise | -2.79% |
| Revenue estimate | 4.365M |
| Revenue actual | 8.223M |
| Revenue Surprise | 88.39% |
Sep 30, 2025
-$0.185 (-0.767%)
| Release date | Oct 30, 2025 |
| EPS estimate | -$0.184 |
| EPS actual | -$0.185 |
| EPS Surprise | -0.767% |
| Revenue estimate | 38.831M |
| Revenue actual | 3.262M |
| Revenue Surprise | -91.60% |
Last 4 Quarters for Hansa Biopharma Ab
Below you can see how HNSBF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Sep 30, 2025
Missed
| Release date | Oct 30, 2025 |
| Price on release | $4.58 |
| EPS estimate | -$0.184 |
| EPS actual | -$0.185 |
| EPS surprise | -0.767% |
| Date | Price |
|---|---|
| Oct 24, 2025 | $3.30 |
| Oct 27, 2025 | $4.58 |
| Oct 28, 2025 | $4.58 |
| Oct 29, 2025 | $4.58 |
| Oct 30, 2025 | $4.58 |
| Oct 31, 2025 | $3.30 |
| Nov 03, 2025 | $4.58 |
| Nov 04, 2025 | $4.58 |
| Nov 05, 2025 | $4.58 |
| 4 days before | 38.79% |
| 4 days after | 0% |
| On release day | -27.95% |
| Change in period | 38.79% |
Dec 31, 2025
Missed
| Release date | Feb 11, 2026 |
| Price on release | $2.91 |
| EPS estimate | -$0.171 |
| EPS actual | -$0.175 |
| EPS surprise | -2.79% |
| Date | Price |
|---|---|
| Feb 04, 2026 | $2.91 |
| Feb 05, 2026 | $2.91 |
| Feb 06, 2026 | $2.91 |
| Feb 10, 2026 | $2.91 |
| Feb 11, 2026 | $2.91 |
| Feb 12, 2026 | $2.91 |
| Feb 17, 2026 | $2.91 |
| Feb 18, 2026 | $2.91 |
| Feb 19, 2026 | $2.91 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Mar 31, 2026
Missed
| Release date | Apr 23, 2026 |
| Price on release | $2.90 |
| EPS estimate | -$0.153 |
| EPS actual | -$0.203 |
| EPS surprise | -33.08% |
| Date | Price |
|---|---|
| Apr 17, 2026 | $2.90 |
| Apr 20, 2026 | $2.90 |
| Apr 21, 2026 | $2.90 |
| Apr 22, 2026 | $2.90 |
| Apr 23, 2026 | $2.90 |
| Apr 24, 2026 | $2.90 |
| Apr 27, 2026 | $2.90 |
| Apr 28, 2026 | $2.90 |
| Apr 29, 2026 | $2.90 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Jun 30, 2026
Missed
| Release date | Jul 22, 2026 |
| Price on release | $2.90 |
| EPS estimate | -$0.0346 |
| EPS actual | -$0.263 |
| EPS surprise | -659.64% |
| Date | Price |
|---|---|
| Jul 16, 2026 | $2.90 |
| Jul 17, 2026 | $2.90 |
| Jul 20, 2026 | $2.90 |
| Jul 21, 2026 | $2.90 |
| Jul 22, 2026 | $2.90 |
| Jul 23, 2026 | $2.90 |
| Jul 24, 2026 | $2.90 |
| Jul 27, 2026 | $2.90 |
| Jul 28, 2026 | $2.90 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Hansa Biopharma Ab Earnings Call Transcript Summary of Q2 2026
Unable to generate transcript summary.
Hansa Biopharma Ab Earnings History
Earnings Calendar
FAQ
When is the earnings report for HNSBF?
Hansa Biopharma Ab (HNSBF) has scheduled its earnings report for Nov 05, 2026 after the markets close.
What is the HNSBF price-to-earnings (P/E) ratio?
HNSBF P/E ratio as of Jul 31, 2026 (TTM) is -4.38.
What is the HNSBF EPS forecast?
The forecasted EPS (Earnings Per Share) for Hansa Biopharma Ab (HNSBF) for the first fiscal quarter 2026 is $0.601.
What are Hansa Biopharma Ab's retained earnings?
On its balance sheet, Hansa Biopharma Ab reported retained earnings of $4.94 million for the latest quarter ending Jun 30, 2026.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
